Galapagos NV
Industriepark Mechelen Noord I, Zone L
Generaal De Wittelaan 11 A
Mechelen
B-2800
Tel: 32-15-34-29-00
Fax: 32-15-34-29-01
Website: http://www.galapagosgenomics.com/
470 articles with Galapagos NV
-
Galapagos reports initiation of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in osteoarthritis patients
9/26/2018
Galapagos NV (Euronext & NASDAQ: GLPG) reports first dosing in the global ROCCELLA Phase 2 trial with GLPG1972/S201086 in knee osteoarthritis patients.
-
Galapagos announces closing of public offering of American Depositary Shares for gross proceeds of €296.2 million
9/19/2018
Galapagos NV announced today the closing of its underwritten public offering of 2,961,373 American Depositary Shares ("ADSs") at a price of $116.50 per ADS
-
Galapagos issues new shares as result of public offering
9/19/2018
Galapagos NV announces a share capital increase as a result of a public offering of American Depositary Shares.
-
Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106
9/14/2018
Galapagos NV and MorphoSys AG announced today the initiation of a Phase 1 bridging study testing a subcutaneous formulation of MOR106, an investigational antibody directed against IL-17C.
-
Galapagos raises $300 million gross proceeds in a U.S. public offering
9/14/2018
Galapagos NV announced today the pricing of its U.S. public offering totaling $300 million gross proceeds of 2,575,107 new ordinary shares in the form of American Depositary Shares ("ADSs") at $116.50 per ADS, before underwriting discounts.
-
MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 with pharma partner
9/13/2018
Galapagos NV and MorphoSys AG announced today the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) in connection with the worldwide, exclusive license agreement with Novartis Pharma AG, entered into on July 19, 2018, for the development and commercialization of their joint program MOR106 (the Collaboration Agreement).
-
Galapagos NV announces launch of proposed public offering
9/13/2018
Galapagos NV announced today that it intends to offer and sell, subject to market and other conditions, $300 million of its ordinary shares in the form of American Depositary Shares (ADSs) in a U.S. public offering.
-
Belgium-based Galapagos NV snagged $300 million following its U.S. public offering of new ordinary shares in the form of American Depositary Shares.
-
Gilead Sciences had a lot of news lately. First off, Gilead and Belgium-based Galapagos NV announced results from their FINCH 2 Phase III clinical trial of filgotinib in adults with moderately-to-severely active rheumatoid arthritis.
-
Gilead and Galapagos Announce TORTUGA Phase 2 Study of Filgotinib in Ankylosing Spondylitis Achieves Primary Endpoint
9/6/2018
Gilead Sciences, Inc.and Galapagos NV today announced that the randomized, placebo-controlled Phase 2 TORTUGA study of filgotinib, an investigational, selective JAK1 inhibitor, achieved its primary efficacy endpoint in adults with moderately to severely active ankylosing spondylitis (AS).
-
With Phase II Win for Ankylosing Spondylitis, Gilead and Galapagos' Filgotinib Inches Toward Appr...
9/6/2018
Gilead Sciences and its partner Galapagos NV announced results from its Phase II TORTUGA clinical trial of filgotinib, a selective JAK1 inhibitor, in adults with moderately to severely active ankylosing spondylitis (AS). -
Galapagos and MorphoSys signed an exclusive development and commercialization deal with Swiss-based Novartis.
-
Is Gilead Poised for a Comeback?
7/6/2018
Gilead may be down, but at least one analyst thinks the company is poised for a turnaround. -
Galapagos Plunges Following Mixed CF Trial Results and AbbVie Decision to Walk Away From Collabor...
6/29/2018
Shares of Galapagos NV fell more than 15 percent Thursday afternoon and continued to fall in premarket trading after the Belgium-based company said AbbVie opted to walk away from its cystic fibrosis collaboration. -
Primary Endpoint Hit: Gilead and Galapagos’ JAK1 Inhibitor for Arthritis Positive in Phase II
5/31/2018
Gilead Sciences and its development partner Galapagos NV announced positive data from its Phase II EQUATOR trial of filgotinib in psoriatic arthritis. -
Gilead and Galapagos Announce Results With Filgotinib in the Phase 2 Equator Study in Psoriatic Arthritis and Progression Into Phase 3 for the Selection Study in Ulcerative Colitis
5/30/2018
Gilead Sciences, Inc. and Galapagos NV announced that the randomized, placebo-controlled Phase 2 EQUATOR study of filgotinib, an investigational, selective JAK1 inhibitor, in 131 adults with moderate to severe psoriatic arthritis, achieved its primary endpoint of improvement in the signs and symptoms of psoriatic arthritis at Week 16.
-
Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atopic dermatitis patients
5/2/2018
Galapagos NV and MorphoSys AG announced today that the first patient has been screened in IGUANA, a Phase 2 study with MOR106.
-
Galapagos presents strong disease-modifying effects in preclinical model of osteoarthritis with GLPG1972 at OARSI 2018
4/29/2018
Galapagos NV presents preclinical results showing broad beneficial effects on cartilage and bone with GLPG1972 in an osteoarthritis (OA) rat model at the Osteoarthritis Research Society International (OARSI) World Congress today in Liverpool, UK.
-
Ahead of next Monday’s U.S. Food and Drug Administration (FDA) committee review of Eli Lilly and Incyte’s baricitinib for rheumatoid arthritis, concerns over blood clots, may scuttle the drug’s chances.
-
ProQR and Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer technology
1/8/2018
The targets that will be pursued in the collaboration and financial details about the collaboration are not disclosed.